Structured evidence table for Citicoline Focus Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Citicoline Focus Randomized Trial | Whilst intraocular pressure (IOP) reduction remains the only evidence-based treatment strategy, disease progression commonly occurs despite adequate IOP control, indicating that IOP-independent mechanisms play critical roles in RGC degeneration. | 4 | Rho Seungsoo (2026) | Prospects for Neuroprotective Therapies in Glaucoma: Drug Targets and Emerging Clinical Strategies |
| Citicoline Focus Randomized Trial | This review synthesizes the current landscape of drug-based neuroprotective strategies, delineates preclinical from clinical evidence, and highlights emerging therapeutic targets. | 4 | Rho Seungsoo (2026) | Prospects for Neuroprotective Therapies in Glaucoma: Drug Targets and Emerging Clinical Strategies |
| Citicoline Focus Randomized Trial | Clinical evidence is detailed inand a summary including preclinical and clinical evidence is shown in. | 4 | Rho Seungsoo (2026) | Prospects for Neuroprotective Therapies in Glaucoma: Drug Targets and Emerging Clinical Strategies |
| Citicoline Focus Randomized Trial | These include excitotoxicity, mitochondrial dysfunction, oxidative stress, neuroinflammation, neurotrophic factor deprivation, and apoptosis (independently or in concert). | 4 | Rho Seungsoo (2026) | Prospects for Neuroprotective Therapies in Glaucoma: Drug Targets and Emerging Clinical Strategies |
| Citicoline Focus Randomized Trial | Irreversible ocular diseases that result in blindness present a significant challenge in contemporary medicine, as no fully effective cure exists; current treatments primarily aim to decelerate disease progression, manage symptoms, and preserve residual vision. | 4 | Wiciński M (2026) | Review of Therapeutic Potential of Coenzyme Q10 in Ophthalmology: Focus on Age-Related Macular Degeneration, Glaucoma, and Retinitis Pigmentosa. |
| Citicoline Focus Randomized Trial | Coenzyme Q10 (CoQ10), a natural antioxidant produced by the human body, has strong anti-inflammatory properties, reduces oxidative stress, and improves mitochondrial function. | 4 | Wiciński M (2026) | Review of Therapeutic Potential of Coenzyme Q10 in Ophthalmology: Focus on Age-Related Macular Degeneration, Glaucoma, and Retinitis Pigmentosa. |
| Citicoline Focus Randomized Trial | With age, endogenously produced CoQ10 levels decline, contributing to the development of chronic diseases, including eye disorders. | 4 | Wiciński M (2026) | Review of Therapeutic Potential of Coenzyme Q10 in Ophthalmology: Focus on Age-Related Macular Degeneration, Glaucoma, and Retinitis Pigmentosa. |
Source documents